Jun Zhao

机构：Chinese Academy of Sciences, Hefei Institutes of Physical Science, Anhui Institute of Optics and Fine Mechanics, Nanjing Medical University · ORCID：0000-0002-4800-7776

发表论文 123 篇 · 总被引 7044 次 · h-index 29

代表论文

• Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study (2024 · Journal of Clinical Oncology · 被引 34)
• First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial (2025 · Journal of Clinical Oncology · 被引 28)
• Consensus on the lung cancer management after third-generation EGFR-TKI resistance (2024 · The Lancet Regional Health - Western Pacific · 被引 27)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 27)
• First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial (2025 · Journal of Thoracic Oncology · 被引 18)
• Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432) (2024 · Signal Transduction and Targeted Therapy · 被引 18)